BioCentury | Apr 6, 2015
Clinical News

DGLA cream: Additional Phase IIa data

...in San Francisco. Dignity previously reported data from the trial (see BioCentury, July 14, 2014). Dignity Sciences Ltd....
BioCentury | Aug 11, 2014
Clinical News

DS107G: Phase I data

...topical formulation of the product, DS107E , to treat atopic dermatitis (see BioCentury, July 14). Dignity Sciences Ltd....
BioCentury | Jul 14, 2014
Clinical News

DGLA cream: Phase II data

...tolerated. Next year, Dignity plans to start Phase III testing with DS107E in the indication. Dignity Sciences...
BioCentury | Jul 10, 2014
Clinical News

Dignity reports Phase II atopic dermatitis data

Dignity Sciences Ltd. (Dublin, Ireland) said 0.1%, 1% and 5% topical DS107E dose-dependently and significantly improved modified Eczema Area and Severity Index (mEASI) scores, the primary endpoint, at day 28 compared to baseline in a...
BioCentury | Mar 5, 2012
Financial News

Dignity Sciences completes venture financing

Dignity Sciences Ltd. , Dublin, Ireland Business: Dermatology, Cardiovascular, Pulmonary Date completed: 3/1/12 Type: Venture financing Raised: €8 million ($10.7 million) Investors: Existing investors WIR Staff Cardiovascular Dermatology Pulmonary...
BioCentury | Mar 2, 2012
Financial News

Irish dermatology company Dignity Sciences raises EUR 8M

Dignity Sciences Ltd. (Dublin, Ireland) raised EUR 8 million ($10.7 million) in a financing led by existing investors. Dignity plans to start Phase II trials this year of DS107 for acne and atopic dermatitis. DS107...
Items per page:
1 - 6 of 6
BioCentury | Apr 6, 2015
Clinical News

DGLA cream: Additional Phase IIa data

...in San Francisco. Dignity previously reported data from the trial (see BioCentury, July 14, 2014). Dignity Sciences Ltd....
BioCentury | Aug 11, 2014
Clinical News

DS107G: Phase I data

...topical formulation of the product, DS107E , to treat atopic dermatitis (see BioCentury, July 14). Dignity Sciences Ltd....
BioCentury | Jul 14, 2014
Clinical News

DGLA cream: Phase II data

...tolerated. Next year, Dignity plans to start Phase III testing with DS107E in the indication. Dignity Sciences...
BioCentury | Jul 10, 2014
Clinical News

Dignity reports Phase II atopic dermatitis data

Dignity Sciences Ltd. (Dublin, Ireland) said 0.1%, 1% and 5% topical DS107E dose-dependently and significantly improved modified Eczema Area and Severity Index (mEASI) scores, the primary endpoint, at day 28 compared to baseline in a...
BioCentury | Mar 5, 2012
Financial News

Dignity Sciences completes venture financing

Dignity Sciences Ltd. , Dublin, Ireland Business: Dermatology, Cardiovascular, Pulmonary Date completed: 3/1/12 Type: Venture financing Raised: €8 million ($10.7 million) Investors: Existing investors WIR Staff Cardiovascular Dermatology Pulmonary...
BioCentury | Mar 2, 2012
Financial News

Irish dermatology company Dignity Sciences raises EUR 8M

Dignity Sciences Ltd. (Dublin, Ireland) raised EUR 8 million ($10.7 million) in a financing led by existing investors. Dignity plans to start Phase II trials this year of DS107 for acne and atopic dermatitis. DS107...
Items per page:
1 - 6 of 6